Acticor Biotech obtains 'PRIME' status from EMA for stroke candidate glenzocimab

22 July 2022

French clinical-stage drug developer Acticor Biotech (EPA: ALACT) announced late Thursday that it has received "PRIority Medicines" status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab, for the treatment of patients with stroke. Acticor’s shares rose 2% to 6.12 euros in early trading today.

Acticor Biotech is a spin-off from INSERM (the French National Institute of Health and Medical Research), which is aiming to develop an innovative treatment for cardiovascular emergencies, including ischemic stroke.

The "PRIME" status granted by the European Medicines Agency (EMA) allows to reinforce the support for the development of drugs that target an unmet medical need. This status will allow Acticor Biotech to strengthen interactions and obtain early dialogues with regulatory authorities in order to confirm the clinical development plan for glenzocimab in the treatment of stroke.

IND cleared in USA

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK